Abstract 180P
Background
HCC is a leading global cause of cancer mortality, particularly in the Asia-Pacific region (APAC). An understanding of RW tx patterns and outcomes in APAC may inform current disease management. Here we report tx patterns and survival outcomes in a RW population of pts from Taiwan and Singapore with intermediate/advanced HCC.
Methods
This secondary data study from the HCC Registry in Asia (NCT03233360) used third-party (IQVIA) de-identified pt-level data collected retrospectively and prospectively from electronic health records from Taiwan and Singapore, including for pts newly diagnosed with HCC from Jan 2013 to Dec 2019. Descriptive statistics were used to summarize tx patterns (sequence, frequency) and pt characteristics by country and BCLC staging B or C; the Kaplan-Meier method was used to estimate median overall survival (mOS).
Results
Pt characteristics by stage and country are in the table. In Singapore in pts with BCLC B (n = 26), TARE/Y90 was the most common 1st tx (50%) followed by resection (19.2%). In BCLC C pts (n = 22) systemic therapies were common (68.2%). In Taiwan, BCLC B pts (n = 51) were often treated with resection (43.1%) or TACE (31.4%); BCLC C pts (n = 46) were most often treated with systemic therapy (41.3%). mOS in BCLC B pts was 21 mo in Singapore and 25 mo in Taiwan. In BCLC C pts mOS was 4 mo in Singapore and 6 mo in Taiwan.
Conclusions
This study showed utilization patterns of available tx options in and characteristics of HCC pts in Singapore and Taiwan despite the limited sample size. HCC RW data from APAC are scarce. This registry’s data collection, still ongoing outside Taiwan and Singapore, provides useful insights into RW practice and outcomes and illustrates urgent need for new tx options for HCC. As new txs emerge such as atezolizumab + bevacizumab for 1st line tx of unresectable or metastatic HCC, future RW studies extending this work will help reveal their RW impact on pts Table: 180P
Pt characteristics, tx frequency and tx sequence in Singapore and Taiwan
BCLC stage | Singapore | Taiwan | ||
B | C | B | C | |
Pts, n | 26 | 22 | 51 | 46 |
Age, years, median (IQR) | 66.0 (62.8-70.6) | 64.0 (60.0-67.8) | 65.4 (57.1-73.1) | 63.1 (55.7-68.1) |
Male, n (%) | 24 (92.3) | 15 (68.2) | 42 (82.4) | 37 (80.4) |
Hepatitis B positive, n (%) | 8 (30.8) | 12 (54.5) | 30 (58.8) | 23 (50.0) |
Pts with subsequent tx, n | 8 | 6 | 3 | 10 |
Most common subsequent tx (%)a | Syst ther (50.0) | Syst ther (83.3) | LRT (66.7) | Syst ther (90.0) |
BCLC, Barcelona Clinic Liver Cancer; LRT, locoregional therapy; Syst ther, systemic therapy; TACE, transarterial chemoembolization; TARE/Y90, transarterial radioembolization with yttrium-90 a % calculated among all pts receiving a subsequent tx
.Clinical trial identification
NCT03233360.
Editorial acknowledgement
Medical writing assistance for this abstract was provided by Chris Lum, PhD of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.
Legal entity responsible for the study
F. Hoffmann-La Roche, Ltd.
Funding
F. Hoffmann-La Roche, Ltd.
Disclosure
S.P. Choo: Honoraria (self), Advisory/Consultancy: eisai; Honoraria (self), Advisory/Consultancy: Bristol Myers Squibb; Speaker Bureau/Expert testimony: DKSH; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Ipsen. S.K. Mhatre: Shareholder/Stockholder/Stock options, Full/Part-time employment: Genentech, Inc. A. Ferro: Full/Part-time employment: Genentech/Roche. R. Machado, D.H-C. Liu, N. Irahara: Full/Part-time employment: Roche. V.E. Gaillard: Shareholder/Stockholder/Stock options, Full/Part-time employment: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
313P - Diagnostic value of micro RNA (miRNA) in renal cell cancer: A meta-analysis and systemic review
Presenter: Jestoni Aranilla
Session: e-Poster Display Session
314P - Comprehensive microbial signatures and genomic profiling in tumour samples using next generation sequencing
Presenter: Mei Qi Yee
Session: e-Poster Display Session
315P - High-penetrance breast and/or ovarian cancer susceptibility genes in Filipinos
Presenter: Frances Victoria Que
Session: e-Poster Display Session
316P - Implementation of Vela Analytics to accelerate comprehensive interpretation and reporting of next-generation sequencing-based oncology testing in clinical diagnostic laboratories
Presenter: Yingnan Yu
Session: e-Poster Display Session
317P - Genomic profiling and molecular pathology of Chinese glioma patients
Presenter: yuanli Zhao
Session: e-Poster Display Session
320P - Psychometric interplay of the perception of the real-life impact of COVID-19 pandemic: A cross-sectional survey of patients with newly diagnosed malignancies
Presenter: Kelvin Bao
Session: e-Poster Display Session
321P - Impact of COVID-19 and lockdown on adherence to treatment schedule among cancer patients
Presenter: Krishnamani Kalpathi
Session: e-Poster Display Session
322P - Challenged faced by cancer patients during the COVID-19 pandemic
Presenter: mithra Krishnamani
Session: e-Poster Display Session
323P - Oncology care in the Republic of Kazakhstan during COVID-19
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
324P - COVID era: Perception of oncologists from a developing nation
Presenter: Rakesh Roy
Session: e-Poster Display Session